Skip to content
TriangleGet started
← Full study record

NCT01797523 · OUTCOME

Percentage of Participants With Toxicities Associated With RAD001, Letrozole, and Metformin

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma · Source last updated 2026-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
93 months

What was measured

To determine the frequency and severity of toxicities associated with RAD001, letrozole, and metformin in this cohort of patients.

Analysis population: 59 patients who had at least one dose of treatment and had a follow up evaluation for side effects

Groups in this outcome

Rad-Let-Met

Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rad-Let-Met59

Reported measurements

Anemia (Grade 2)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met85Not reportedNot reportedNot reportedNot reported
Anemia (Grade 3)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met24Not reportedNot reportedNot reportedNot reported
Hypertriglyceridemia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met15Not reportedNot reportedNot reportedNot reported
Hyperglycemia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met9Not reportedNot reportedNot reportedNot reported
Hyponatremia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met7Not reportedNot reportedNot reportedNot reported
Fatigue
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met6Not reportedNot reportedNot reportedNot reported
Thrombocytopenia
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        85
    title
    Anemia (Grade 2)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        24
    title
    Anemia (Grade 3)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        15
    title
    Hypertriglyceridemia
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        9
    title
    Hyperglycemia
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Hyponatremia
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Fatigue
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Thrombocytopenia
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
To determine the frequency and severity of toxicities associated with RAD001, letrozole, and metformin in this cohort of patients.
groups
  1. description
    Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule
    id
    OG000
    title
    Rad-Let-Met
param Type
NUMBER
population Description
59 patients who had at least one dose of treatment and had a follow up evaluation for side effects
reporting Status
POSTED
time Frame
93 months
title
Percentage of Participants With Toxicities Associated With RAD001, Letrozole, and Metformin
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice